Compared with non-carriers, g<i>BRCA1/2</i> carriers were significantly younger at mBC diagnosis (47.5 vs. 60.7 years, <i>p</i> = 0.0006), had higher-grade tumor histology (<i>p</i> = 0.044), and had a higher rate of contralateral recurrence (36.4% vs. 11.6%, <i>p</i> = 0.035), with comparable adjusted survival (median overall survival 74.9 vs. 100.1 months, <i>p</i> = 0.97). This evidence concerns the gene BRCA1 and neoplasm.